L
-arginine metabolism in macrophages is regulated by the enzymes arginase I (Arg1) and inducible NO synthase (iNOS), which produce urea and ornithine (precursor for synthesis of polyamines and pralines) or citrulline and the inflammatory mediator NO, respectively (1) . Divergent expression of Arg1 and iNOS has contributed to the dichotomous nomenclature of macrophages (2, 3) . M1 (or classically activated) macrophages express high levels of iNOS and low levels of Arg1 and participate in the clearance of intracellular pathogens. Conversely, M2 (or alternatively activated) macrophages express the reverse pattern and not only develop in response to parasitic infections in a Th2 cytokine-dependent manner (4) but also protect host tissue from inflammatory damage (5) . Whereas dysregulated expression of iNOS by M1 macrophages promotes inflammatory damage, as occurs in atherosclerosis (6, 7) , excess expression of Arg1 by M2 macrophages thwarts effective immunity against intracellular pathogens (8) and exacerbates tumor growth (9) (10) (11) . Thus, during both the initiation and resolution of immunity, expression of iNOS and Arg1 in macrophages must be tightly regulated to protect the host from potentially damaging inflammation.
Tumor-associated macrophages (TAMs) represent a substantial fraction of the growing tumor mass and are associated with poor prognosis in many human tumors (12) (13) (14) . TAMs play disparate roles in tumor progression, depending on their phenotypic properties. M2 skewed macrophages promote tumor growth by virtue of their proangiogenic and prometastatic properties. In addition, high levels of Arg1 expression in TAMs results in depletion of its substrate, L-arginine, from the extracellular environment, decreased CD3z chain expression in T cells, and inhibition of Agspecific T cell proliferation (10) . Tie2-expressing macrophages (TEMs) compose a TAM subset that expresses high levels of Arg1 and has an anti-inflammatory and proangiogenic (i.e., M2) phenotype (15) . Selective depletion of this TAM subset results in inhibition of both angiogenesis and tumor growth (16) . Thus, targeting the tumor-promoting activity of TAMs, including the expression of Arg1, has important therapeutic implications.
Receptor tyrosine kinases (RTKs) are involved in the initiation and progression of a variety of human malignancies and are targets for molecular intervention. Expression of the Ron RTK is markedly elevated in a large percentage of epithelial cancers derived from breast (56%), colon (51%), lung (48%), thyroid (42%), skin (37%), bladder (36%), and pancreas (33%) (17) , and constitutively active splice variants of Ron have been isolated from human colorectal carcinoma cells (18) . Increased expression and constitutive phosphorylation of Ron has been observed in primary breast carcinomas, whereas normal breast epithelial cells, as well as cells in benign lesions (adenomas and papillomas), express comparatively low levels of Ron (19) . Moreover, increased expression of Ron or its ligand, macrophage stimulating protein (MSP), in human breast carcinomas is associated with aggressive disease and poor prognosis (20) . Thus, Ron is a promising target for therapeutic intervention against malignant phenotypes (21) .
Ron is also expressed on tissue-resident macrophages and suppresses hallmarks of M1 activation, including expression of iNOS, IL-12p40, and TNF-a in primary macrophages stimulated with IFN-g and LPS (22, 23) . This inhibition is due to the ability of Ron to inhibit Stat1 phosphorylation in response to IFN-g (22, 24) and to inhibit NF-kB activation in response to LPS (23, 25) . Ron 2/2 mice express elevated levels of IL-12p40 after endotoxin challenge, resulting in enhanced IFN-g production by NK cells and increased susceptibility to septic shock (24) . Furthermore, the absence of Ron leads to enhanced inflammation in animal models of multiple sclerosis (26) , acute lung injury (27) , and delayed-type hypersensitivity (28) . Taken together, these observations indicate that Ron plays a central role in limiting Th1-mediated inflammatory responses.
In addition to its role in suppressing inflammation, we have demonstrated that Ron promotes hallmarks of an M2, or antiinflammatory, phenotype in primary macrophages, as exemplified by the upregulation of Arg1, scavenger receptor, and IL-1 receptor antagonist expression (29) . While numerous studies have addressed the role of RTKs, including Ron, in the promotion of tumor cell growth and metastasis in a cell-autonomous manner, the potential role of these receptors in the tumor microenvironment remains poorly defined. In this study, we demonstrate that Ron induces Arg1 expression through a previously uncharacterized AP-1 binding site in the Arg1 promoter. We further demonstrate that Ron promotes Arg1 expression in vivo in TAMs and that Ron expression in the tumor microenvironment promotes tumor growth. In addition to the well-established role of RTKs in promoting tumor growth in a cell-autonomous manner, our findings indicate that therapeutic targeting of an RTK in the tumor microenvironment could retard tumor growth and improve clinical outcome.
Materials and Methods

Mice, cells, and reagents
Six-to ten-week-old C57BL/6 mice or Ron 2/2 mice, described previously (28), were used for this study. HEK293T, 3LL, and B16-F10 cells were purchased from American Type Culture Collection (Manassas, VA). EG.7 cells were kindly provided by Dr. Avery August (The Pennsylvania State University, University Park, PA). Cells were maintained in DMEM supplemented with L-glutamine, nonessential amino acids, sodium pyruvate (CellGro; Mediatech, Manassas, VA), 10% FBS (Life Technologies, Gaithersburg, MD) and 10 mg/ml ciprofloxacin (Serologicals Proteins, Kankakee, IL). Abs for Western blot analysis were phospho-p44/42, phospho-Gab1 (Y307), phospho-Gab2 (Y452 and S159), p44/42, Gab1, Gab2 (Cell Signaling, Beverly, MA), actin (Sigma, St. Louis, MO), c-Fos (sc-253; Santa Cruz Biotechnology, Santa Cruz, CA), and Arg1 (BDTransduction Laboratories, San Jose, CA). Abs for flow cytometry and FACS were CD16/32 Fc-block, CD11b allophycocyanin-750, Gr1-FITC, CD4-Cy5, CD8-FITC, CD31-FITC, streptavidin-PE (BD Pharmingen, San Diego, CA), Gr1-FITC, CD11b-allophycocyanin-eFluor780, MRC1-biotin (BioLegend, San Diego, CA), CD11cPC7 (eBioscience, San Diego, CA), F4/80 RPE (Serotec, Raleigh, NC), anti-Ron (R&D Systems, Minneapolis, MN), and anti-goat Alexa Fluor 647 (Molecular Probes, Eugene, OR). Abs used for chromatin immunoprecipitation (ChIP) analysis were Stat6 (sc-1698x) and Fos (sc-52x) from Santa Cruz Biotechnology. Recombinant human MSP-C632A and murine IL-4 were purchased from R&D Systems. MAPK inhibitors used were U0126 (Cell Signaling), SB2035801, and SP600125 (Cayman Chemicals, Ann Arbor, MI). The Pennsylvania State University Institutional Animal Care and Use Committee approved all animal experiments.
Flow cytometry
Single-cell suspensions of splenocytes were achieved using a Dounce homogenizer. RBCs were lysed for 15 min on ice using ACK buffer (0.15 M NH 4 Cl, 1 mM KHCO 3 , 0.1 mM Na 2 EDTA pH 7.4) and resuspended in FACS buffer (ice-cold PBS plus 2% FBS). Cells (3 3 10 6 ) were stained in 100 ml FACS buffer with indicated Abs. Dissected and minced tumors were digested with 0.05% collagenase type IV (Sigma) for 30 min at 37˚C and filtered through 70-mm nylon mesh (BD Falcon) to achieve single-cell suspensions. Cells were stained with the indicated Abs and analyzed on a Beckman FC500 flow cytometer.
Macrophage isolation
Resident peritoneal macrophages were extracted from 6-to 10-wk-old C57BL/6 or FVB mice as previously described (29) and incubated at 37˚C for 2 h prior to stimulation. Thioglycolate-elicited macrophages were prepared by injecting 2-mo-old C57BL/6 mice with 2 ml 3% aged thioglycolate media (Difco, Sparks, MD). On day 4, cells were isolated by lavage and prepared as above for resident macrophages. Myeloid-derived suppressor cells (MDSCs) and TAMs were isolated from spleen or tumor cell suspensions from day 15 3LL tumor-bearing mice by FACS with Abs to CD11b, Gr1, and F4/80 using a Cytopeia influx cell sorter. TEMs and inflammatory TAMs (15) were isolated from MMTV-PyMT spontaneous mammary tumors (14 wk of age). Tumors were excised and made into single-cell suspensions by collagenase IV (0.2 mg/ml; Worthington), dispase (2 mg/ml; Life Technologies), and DNaseI (0.1 mg/ml; Roche) treatment. Before sorting, all cell suspensions were incubated with rat antimouse FcgIII/II receptor (CD16/CD32) blocking Abs together with mAbs and 7-aminoactinomycin D (7-AAD) to stain nonviable cells. 
Plasmid construction
Identification of Arg1 promoter binding sites was performed using MatInspector software by Genomatix (Ann Arbor, MI). Arg1 reporter constructs, except the AP-1 mutant, were described previously (30) . Mutagenesis of the AP-1 site was performed using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA): forward primer, 59-CCCAGAA-CTTGAAGCCTTGTTGCAGGATGCTCAACAGGAGG-39; (underline indicates site of mutation) reverse primer, 59-CCTCCTGTTGAGCATCCT-GCAACAAGGCTTCAAGTTCTGGG-39. Ron and Src constructs were described previously (31, 32) .
Luciferase assay
293T cells (6 3 10 5 ) were plated per well in 24-well plates. After 16 h, cells were transfected with 15 ng/well Arg1 promoter, PCI-Ron or PCINeo control, and 0.5 ng/well Renilla luciferase plasmids using Mirus Transit-293 transfection reagent (Mirus, Madison, WI). Twenty-four hours posttransfection, cells were stimulated with MSP (100 ng/ml) for 20 h, and luciferase activity was measured using the Dual Luciferase reporter system (Promega, Madison, WI). Renilla luciferase activity was used to normalize for transfection efficiency. For Arg1 promoter deletion constructs, equimolar amounts of the plasmids were added and balanced to the 3.29 construct with PCI-Neo. For experiments with the Src constructs, 100 ng/ well of plasmid was added.
Western blot analysis
Resident peritoneal macrophages (1 3 10 6 ) or thioglycolate-elicited macrophages (3 3 10 6 ) were stimulated with MSP (100 ng/ml) or IL-4 (10 ng/ml). Cells were washed in PBS and lysed for 30 min at 4˚C in RIPA buffer containing protease and phosphatase inhibitors [10 mM Tris-HCL, pH 7.5, 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate, NaF (10 mM), Na 3 VO 4 (4 mM), PMSF (1 mM), aprotinin (10 mg/ml), leupeptin (10 mg/ml), and pepstatin A (1 mg/ml)]. Lysates were cleared by centrifugation at 14,000 3 g, separated by SDS-PAGE, and transferred onto Immobilon-P polyvinylidene fluoride membranes (Millipore, Bedford, MA). Blots were incubated overnight with primary Ab at 4˚C. Anti-rabbit and anti-mouse HRP-conjugated secondary Abs were added for 45 min at room temperature. ECL Plus (Amersham, Piscataway, NJ) was used to develop the blots.
Quantitative RT-PCR
For mRNA expression analysis in resident peritoneal macrophages, 1 3 10 6 cells were stimulated with MSP (100 ng/ml). RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA). Reverse transcription was carried out using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). One hundred nanograms of cDNA, 300 nM of each primer, and 20 nM of probe were used per quantitative PCR (qPCR) with TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA), and reactions were run and analyzed using an ABI7300. Gapdh (Applied Biosystems) was used as an internal control. Arg1 primers: forward, 59-TTGGGTGGATGCTCACACTG-39; reverse, 59-TTG-CCCATGCAGATTCCC-39; probe, 59-CATCAACACTCCCCTGACAAC-CAGCTC-39. Gene-specific primer and probe sets for Mrc1, Clec7a, Chi3l3, Retnia, Tnf, Il1b, Il6, Il12b, and Inos were purchased from Applied Biosystems.
For Ron and ArgI comparative gene expression in TEMs, inflammatory TAMs, and resident peritoneal macrophages, mRNA from at least 2.5 3 10 4 to 10 3 10 4 cells was purified following the RNeasy Micro kit guidelines (Qiagen). RNA was retrotranscribed with SuperScript III (SuperScript VILO cDNA Synthesis Kit; Invitrogen). qPCR analyses were performed with TaqMan probes from Applied Biosystems using an ABI7900HT (Applied Biosystems). To calculate differences in mRNA levels of Ron and Arg1 in TEMs and inflammatory TAMs, b2m and Gapdh were used as reference genes, respectively. Statistical analysis of the data was performed on actual DC t values by Student t test on two biological replicates. To compare mRNA levels of Ron and Arg1 in TEMs, inflammatory TAMs, and resident peritoneal macrophages, Ron and ArgI mRNA copies are expressed as relative to b2m mRNA copies. Statistical analysis of the data was performed on actual DC t values by Student t test on three (TEMs and inflammatory TAMs) or two (resident peritoneal macrophages) biological replicates.
Arginase activity assay
Primary resident peritoneal macrophages were treated with the indicated inhibitors for 2 h followed by MSP or IL-4 treatment for 4 h. Cells were lysed with 100 ml 0.1% Triton X-100. After 30 min on a shaker, 100 ml 25 mM Tris-HCl was added. To 100 ml of this lysate, 10 ml 10 mM MnCl 2 was added, and the enzyme was activated by heating for 10 min at 55˚C. Arginine hydrolysis was conducted by incubating the lysates with 100 ml 0.5 M L-arginine (pH 9.7) at 37˚C for 60 min. The reaction was stopped with 800 ml H 2 SO 4 (96%)/H 3 PO 4 (85%)/H 2 O (1:3:7, v/v/v). The urea concentration of samples and standards was measured at 550 nm after addition of 40 ml a-isonitrosopropiophenone (Sigma-Aldrich) (dissolved in 100% ethanol), followed by heating at 100˚C for 30 min.
ChIP
Resident or thioglycolate-elicited peritoneal macrophages stimulated with 100 ng/ml MSP or 10 ng/ml IL-4 were fixed with 1% formaldehyde for 10 min at room temperature and quenched with 0.125 M glycine for 5 min. Then, 10 3 10 6 cells/sample were spun at 2000 3 g at 4˚C for 5 min and resuspended in 300 ml cell lysis buffer [50 mM Tris-HCL pH 8, 10 mM EDTA, 1% SDS, and protease inhibitors (aprotinin 10 mg/ml, leupeptin 10 mg/ml, and pepstatin A 1 mg/ml)]. Chromatin was sonicated using the Diagenode Bioruptor (power setting high, 20 cycles of 30 s on, 60 s off) yielding DNA of 200-600 bp in length. Samples were centrifuged at 14,000 3 g for 15 min at 4˚C to remove debris. The volume equivalent of 1.5 3 10 6 resident or 4 3 10 6 thioglycolate-elicited macrophages was aliquoted into 103 ChIP dilution buffer (0.5% Triton X-100, 2.2 mM EDTA, 22 mM Tris-HCL pH 8, 150 mM NaCl plus protease inhibitors) and incubated overnight at 4˚C with primary Ab (3 mg/ml). The next morning, 20 ml protein A or G magnetic beads (New England Biolabs, Beverly, MA) was added for 2 h at 4˚C. Beads were collected by magnetic isolation and washed three times with 1 ml of low-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH 8.1, 150 mM NaCl) and twice with TE. Complexes were reverse cross-linked in 140 ml elution buffer (20 mM Tris-HCl pH 8, 5 mM EDTA, 50 mM NaCl, 1% SDS, 125 mg/ml proteinase K) at 65˚C for 3 h. DNA was collected using DNA Clean and Concentrator (Zymo Research, Orange, CA). Two microliters of DNA per qPCR reaction using SensiMix SYBR (Bioline, Taunton, MA) was analyzed on an ABI7900HT. Primers used were as follows. AP-1 site: forward, 59-GCCCCATGCTTTCCTAGACA-39; reverse, 59-GAGCATCCTGAGTCAAGGCTTC-39. Stat6 site: forward, 59-GCATTGTTCAGACTTCCTTATGCTT-39; reverse, 59-TGTTGGCTAA-TACAGCCTGTTCAT-39.
Tumor measurements
The indicated tumor cells were grown to confluence, trypsinized, and resuspended in PBS. One hundred microliters containing 5 3 10 5 cells was injected s.c. into the shaved right flank of wild-type or Ron 2/2 mice. Upon onset of palpable tumor growth, mice were examined every other day by caliper for tumor volume as determined by the formula ab 2 3 0.4, where a is the length and b is the width.
Mixed lymphocyte reaction
Splenocytes from tumor-free BALB/c mice were gamma-irradiated, and Ag-specific challenge of splenocytes and ELISA Splenocytes were collected from day 15 EG.7 mice and lysed with ACK lysis buffer as above. Splenocytes (5 3 10 6 ) were added per well of a 24-well plate in 600 ml of complete DMEM. One milliliter containing 4 3 10 5 gamma-irradiated EG.7 cells (5000 rad) were added to each well of the coculture. Cells were incubated at 37˚C for 3 d at which time an additional 400 ml containing 6 3 10 5 gamma-irradiated EG.7 cells was added. On day 4, plates were centrifuged at 250 3 g for 5 min, and 1 ml of supernatant was collected for ELISA analysis using BD OptEIA kits (BD Pharmingen).
Multiplex cytokine assay
Serum was collected from euthanized mice by cardiac puncture on days 7, 11, and 15 from EG.7 wild-type and Ron 2/2 tumor-bearing mice (TBM). Serum was analyzed for IP10 using the LincoPlex assay kit (Millipore).
Statistical analysis
Minitab software was used for statistical analysis. Student t test, ANOVA, and MANOVA were used as indicated. Differences were considered significant at p , 0.05.
Results
Ron inhibits expression of inflammatory mediators and promotes expression of Arg1 in primary macrophages
M1-and M2-polarized macrophages, induced by IFN-g and TLR agonists versus IL-4 and IL-13, respectively, represent the end points of a continuum of macrophage phenotypes responsible for such diverse functions as sensing the presence of microbes and promoting immunity to infection, phagocytosis of a wide array of pathogen-and host-derived factors, and resolution of inflammation and tissue repair. We have shown previously that Ron inhibits the induction of iNOS and IL-12p40 in response to M1-polarizing signals while promoting the upregulation of Arg1. To assess further the role of Ron in the regulation of these polarized phenotypes, we stimulated primary peritoneal macrophages with MSP and assessed the expression of a panel of M1-and M2-associated genes by real-time PCR. MSP alone induced expression of Il1b and Il6, markers of M1 macrophage activation, and Arg1 and Clec7a (the gene encoding Dectin-1), markers of M2 macrophage activation (Fig. 1A) . Primary macrophages were also stimulated with LPS or IL-4 to polarize cells toward an M1 or M2 phenotype, respectively, after overnight stimulation with MSP. As demonstrated previously, MSP inhibited expression of the M1 markers Inos, Il12b (the gene encoding IL-12p40), Tnf, and Il1b, but not Il6, in the presence of LPS (Fig. 1B) . The expression of the M2 markers Mrc1, Chi3l3 (the gene encoding Ym-1), and Retnla (the gene encoding Fizz-1) by IL-4 was also significantly reduced in the presence of MSP (Fig. 1C) ; however, expression of Arg1 was maintained or slightly increased under these conditions. This observation suggests the possibility that, in addition to Th1-mediated inflammation, Ron could also play a role in the inhibition of Th2-mediated inflammation, during which macrophagederived Arg1 plays a protective role.
Ron induces Arg1 promoter activity
To determine the mechanism underlying the induction of Arg1 by Ron, we used a previously described Arg1 luciferase reporter containing 3.29 kb DNA upstream of the transcription start site
The Journal of Immunology(TSS) of the Arg1 promoter (30) . The Arg1 reporter was transiently transfected with or without a cDNA encoding Ron in 293T cells, and luciferase activity was measured. Reporter activity increased markedly in Ron-expressing cells and was further induced by stimulation with MSP ( Fig. 2A) . This confirms that Ron induces Arg1 expression by regulating Arg1 promoter activity. Two docking site tyrosines (Y1330 and Y1337) in the C-terminal tail of Ron mediate cell signaling and phenotypic events in response to MSP (31) . To determine whether the docking site tyrosines are required for induction of Arg1 promoter activity by Ron, we cotransfected Ron-Y2F (Y1330/37F), Ron-Y1330F, or RonY1337F with the Arg1 reporter plasmid and examined luciferase activity in the presence and absence of MSP. As expected, Ron-Y2F failed to induce Arg1 reporter activity in response to MSP stimulation (Fig. 2B) . However, MSP retained its ability to induce Arg1 promoter activity upon stimulation of the single docking site tyrosine mutants RonY1330F or Ron-1337F, indicating that these docking site tyrosines induce overlapping signaling pathways that are required for the induction of Arg1 promoter activity in response to MSP stimulation.
Ron also induces Arg1 promoter activity in these cells in the absence of ligand (Fig. 2A) . Previously, we found that ligandindependent induction of cell signaling by Ron is independent of the docking site tyrosines but dependent on tyrosines 1175, 1265, and 1294 in the kinase domain of Ron, in a Src kinasedependent manner (31) . To determine whether these tyrosines are responsible for ligand-independent induction of Arg1 promoter activity by Ron, we cotransfected the Arg1 promoter with a Ron mutant harboring tyrosine-to-phenylalanine mutations at positions 1175, 1265, and 1294 (Y3F) and compared reporter activity with that induced by the wild-type receptor. Although the Y3F mutant was unable to induce reporter activity in a ligand-independent manner, it retained its ability to induce Arg1 reporter activity in response to MSP stimulation (Fig. 2C) . To determine whether the ligand-independent induction of Arg1 is mediated by Src, we cotransfected Ron with either wild-type or dominant-negative Src and assessed Arg1 reporter activity. Cotransfection with dominant-negative Src inhibited Ron-mediated Arg1 reporter activity to control levels, but MSP-induced activity was retained (Fig. 2D) .
Ron regulates Arg1 expression through an AP-1 site in the promoter proximal region
To identify the region of the Arg1 promoter responsible for mediating its induction by Ron, we used a previously described series of 59-terminally deleted promoter constructs (30) . A Stat6 binding element ∼2.9 kb upstream of the TSS is critical for the induction of Arg1 promoter activity by IL-4 and IL-13 (30, 33) . However, FIGURE 1. Ron regulates M1 and M2 macrophage activation. A, Primary resident peritoneal macrophages were stimulated for 4 h with 100 ng/ml MSP, and expression of genes associated with M1 and M2 macrophage activation were assessed by real-time PCR. B, Primary peritoneal macrophages were cultured overnight with or without MSP followed by stimulation with 100 ng/ml LPS for 4 h, and the expression of genes associated with M1 macrophage activation was assessed by real-time PCR. C, Primary peritoneal macrophages were cultured overnight with or without MSP followed by stimulation with 5 ng/ml IL-4 for 4 h, and expression of genes associated with M2 macrophage activation was assessed by real-time PCR. Results are the average of two independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001. deletion of this region did not result in a significant loss in promoter activity induced by Ron in the presence or absence of MSP. Alternatively, the region between 20.8 and 20.3 kb of the promoter was critical for the induction of Arg1 promoter activity by Ron in the presence or absence of ligand (Fig. 2E) . Our results indicate that induction of the Arg1 promoter by Ron occurs via a mechanism distinct from that previously observed for Th2 cytokines IL-4 and IL-13.
We used MatInspector software to search the region between 20.8 kb and 20.3 kb of the Arg1 promoter for potential transcription factor binding sites. Of the potential sites identified, we focused on a match to the consensus binding site for AP-1 (TGAc/ gTCA), a MAPK-responsive element, located 433 bp upstream of the TSS. To determine whether this binding site contributes to induction of Arg1 promoter activity by Ron, we mutated the AP-1 site in the context of the 23.29-kb and 20.8-kb Arg1 reporter constructs, cotransfected the reporter constructs with Ron in 293T cells, and measured luciferase activity. In the context of both the 3.29-kb (Fig. 2F) and the 0.8-kb (data not shown) promoter fragments, the AP-1 mutation abolished Ron-induced reporter activity, whereas mutation of the upstream Stat6 element, previously identified as an IL-4-responsive site, did not decrease FIGURE 2. Ron induction of Arg1 promoter activity is mediated by an AP-1 binding site. A-C, 293T cells were cotransfected with the indicated Ron constructs or Neo control, Renilla, and a luciferase reporter driven by a 3.29-kb fragment of the Arg1 promoter. After transfection, cells were left unstimulated or stimulated with MSP for 20 h, and luciferase reporter activity was measured and normalized to Renilla. D, 293T cells were cotransfected with Ron or Neo, Renilla, and wild-type Src (WT Src) or dominant-negative Src (DN Src) as indicated. Arg1 reporter activity was measured and normalized to Renilla. Equivalent expression of Ron was confirmed in all experiments by Western blot analysis (data not shown). Data are presented as mean 6 SD and are representative of three or more independent experiments. E, 293T cells were cotransfected with Ron or Neo control, Renilla, and the indicated series of 59-terminally deleted Arg1 promoter constructs. After transfection, cells were left unstimulated or stimulated with 100 ng/ml MSP for 20 h, and luciferase reporter activity was measured and normalized to Renilla. F, 293T cells were cotransfected with Ron or Neo, Renilla, and the 3.29-kb Arg1 promoter construct with or without mutations in the AP-1 binding site or the Stat6 binding site as indicated. Arg1 reporter activity was measured and normalized to Renilla. Data are presented as mean 6 SD and are representative of five independent experiments. Ron-induced activity. Specificity of the AP-1 mutations was confirmed by testing mutations that flank the AP-1 site. These mutants did not result in the loss of activity (data not shown).
MSP induces MAPK signaling in primary macrophages
Consistent with the ability of Ron to induce Arg1 activity in an AP-1-dependent manner, MSP stimulation of primary peritoneal macrophages induced strong and sustained activation of the MAPK Erk, compared with weak and transient induction of Erk in these cells by the Th2 cytokine IL-4 (Fig. 3A) . Consistent with these results, MSP, but not IL-4, induced robust expression of c-Fos in these cells. Activation of MAPK signaling downstream of Ron is mediated by the IRS-related adapter proteins Gab1 and Gab2. Docking site Y1330 binds directly to Gab1 via a Met binding domain (34) , whereas Grb2 binds to the second docking site Y1337 and thereby indirectly recruits either Gab1 or Gab2 (35, 36) . MSP induced strong phosphorylation of both Gab1 and Gab2 in primary peritoneal macrophages. This induction was not observed in macrophages stimulated with IL-4.
To determine the time frame during which Arg1 transcription is induced by MSP in primary macrophages, Arg1 mRNA levels were quantified by quantitative RT-PCR. Whereas MSP induction of Arg1 expression was observed as early as 1 h poststimulation, the induction pattern was biphasic (Fig. 3B) . The timing of the early phase (1-4 h poststimulation) of Arg1 induction by MSP mirrored that observed for the upregulation of c-Fos expression and the phosphorylation of Gab1, Gab2, and Erk in these cells (Fig. 3A) , suggesting that this early wave of expression could be regulated by AP-1. To determine whether the induction of Arg1 by MSP is MAPK dependent, we stimulated primary peritoneal macrophages with MSP or IL-4 in the presence and absence of the MAPK inhibitors U0126 (MEK inhibitor), SB203580 (p38 inhibitor), and SP600125 (Jnk inhibitor), and assessed Arg1 activity (Fig. 3C) . The induction of Arg1 by MSP was completely inhibited by MEK inhibitor, suggesting that the upregulation of c-Fos expression by MSP could play a critical role in the induction of Arg1. None of these inhibitors had an adverse effect on the induction of Arg1 activity by IL-4.
MSP induces binding of c-Fos to the Arg1 promoter
To determine whether MSP induces AP-1 binding to the Arg1 promoter in primary macrophages at this early time point, we performed ChIP 2 h after MSP stimulation. qPCR for the AP-1 site was performed on chromatin immunoprecipitates to detect binding of the AP-1 family member Fos. Consistent with our in vitro results, we observed a 4-fold enrichment of Arg1 DNA by Fos ChIP in response to MSP, whereas IL-4, a weak MAPK activator, failed to induce significant Fos binding at this site (Fig.  4A) . Conversely, whereas IL-4 induced 10-fold enrichment of DNA by immunoprecipitation of Stat6 at the IL-4-response element (Fig. 4B) as previously described (33), MSP induced little or no binding of Stat6 to the IL-4-response element. This is consistent with results in Fig. 2 showing that the Stat6 site plays no role in the induction of Arg1 by MSP. To confirm these results, we performed similar studies in thioglycolate-elicited macrophages. We confirmed Ron expression in thioglycolate-elicited macrophages by flow cytometry (Fig. 4C ) and demonstrated that stimulation of these cells with MSP promoted Erk phosphorylation (Fig. 4D) and induced the upregulation of Arg1 mRNA (Fig. 4E) . ChIP analysis in these cells confirmed binding of Fos to the AP-1 site in response to MSP (Fig. 4F) . Taken together, our results suggest that MSP initiates Arg1 transcription in primary macrophages through induction of AP-1 binding to the Arg1 promoter.
Ron promotes expression of Arg1 in tumor-associated macrophages in vivo
TAMs express high levels of Arg1 (10). To determine whether Ron regulates Arg1 expression in vivo, we examined Arg1 expression in CD11b + /F480 + TAMs from wild-type and Ron 2/2 animals. A, Resident peritoneal macrophages were either unstimulated or stimulated with 100 ng/ml MSP or 10 ng/ml IL-4 for the indicated times. Cell lysates were isolated, and levels of phosphorylated Erk (pErk), total Erk, cFos, phosphorylated Gab2 (pGab2Y452 and pGab2S159), total Gab2, phosphorylated Gab1 (pGab1Y307), total Gab1, and actin were assessed by Western blot analysis. Data are representative of two or more independent experiments. B, Resident peritoneal macrophages were stimulated with 100 ng/ml MSP for the indicated times, and RNA was collected for quantitative RT-PCR analysis. Data are presented as mean 6 SD and are representative of four independent experiments. C, Resident peritoneal macrophages were stimulated with DMSO, 10 mM U0126, 10 mM SB203580, or 20 mM SP600125 for 2 h followed by stimulation for 24 h with 100 ng/ml MSP or 5 ng/ml IL-4, and arginase activity was assessed. Results are the average of two independent experiments. ***p , 0.001.
Consistent with the ability of Ron to induce Arg1 expression in primary macrophages in vitro, TAMs isolated from Ron 2/2 TBM exhibited reduced Arg1 expression compared with wild-type controls (Fig. 5A ). Arg1 regulation was independent of TAM recruitment to the tumor microenvironment as the percentage of TAMs in wild-type and Ron 2/2 mice did not differ significantly (Fig. 5B) . F480 + TAMs can be further divided into two main, non-overlapping subsets based on the expression of CD11c and the mannose receptor (MRC1) (15) . F480 + /CD11c + TAMs express high levels of proinflammatory and anti-angiogenic cytokines and have been termed "inflammatory TAMs" (15) . Conversely, F480 + / MRC1 + TAMs express lower levels of proinflammatory molecules and higher levels of proangiogenic and tissue-remodeling molecules than inflammatory TAMs. These M2-skewed TAMs express Tie2 and are also known as TEMs (15) . These two TAM subsets coexist in tumors, where they exert distinct and perhaps opposing functions (15) . In contrast to barely detectable expression of Ron in CD11c + inflammatory TAMs, expression of Ron was increased by an average of 12-fold in MRC1 + TEMs (Fig.  5C ). In addition, MRC1
+ TEMs express elevated levels of Arg1 compared with CD11c + inflammatory TAMs (Fig. 5D) . These results suggest that regulation of Arg1 expression by Ron occurs within the MRC1 + subset of TAMs. Resident peritoneal macrophages expressed higher Ron mRNA levels than tumor-derived macrophages (Fig. 5E ). However, there was a clear correlation between the expression levels of Ron and Arg1 in each population analyzed (Fig. 5F ).
Reduced syngeneic tumor growth in Ron 2/2 mice Arg1 expression in TAMs has been implicated in promoting tumor growth. To determine whether decreased Arg1 expression in Ron
TAMs correlates with decreased tumor growth, wild-type and Ron 2/2 animals were injected s.c. with 3LL (non-small cell Lewis lung carcinoma), B16-F10 (melanoma), or EG.7 (lymphoma) tumor cell lines, and tumor growth was assessed. As shown in Fig.  6A -C, Ron 2/2 mice develop smaller tumors than their wild-type counterparts. In all cases, differences in tumor growth are observable as early as can be reasonably assessed by caliper measurement and persist throughout the duration of the experiment. CD11b + /Gr1 + MDSCs increase in numbers within secondary lymphoid organs upon tumor onset. Whereas MDSC expansion was increased in the spleens of wild-type TBM, expansion of MDSCs was attenuated in Ron 2/2 animals (Fig. 6D) . We also Thioglycolate-elicited macrophages were stimulated with 100 ng/ml MSP for the indicated times, and lysates were immunoblotted for phosphorylated Erk. E, Thioglycolate-elicited macrophages were stimulated with 100 ng/ml MSP for 2 h and assessed for Arg1 expression by quantitative RT-PCR. F, Thioglycolate-elicited macrophages were stimulated with 100 ng/ml MSP for 2 h, and Fos binding to the AP-1 site in the Arg1 promoter was assessed by ChIP and subsequent qPCR. Data are presented as mean 6 SD, normalized to unstimulated macrophages, and are representative of two independent experiments. observed a reduction in MCP-1, G-CSF, IL-6, and IL-1, which participate in the recruitment of MDSCs, in the sera of Ron 2/2 TBM (Fig. 7) . MDSCs inhibit both Ag-specific and alloreactive T cell activation. Consistent with the decrease in splenic MDSCs in Ron 2/2 mice, the numbers of CD4 + and CD8 + T cells in the spleens of Ron 2/2 TBM were higher than those from wild-type TBM (Fig.   8A ). To determine whether these cells exhibit increased proliferation in response to allogeneic stimulation, we performed an MLR. When splenocytes from C57BL/6 TBM were used as responders to gamma-irradiated BALB/c splenocytes, a greater proliferative response was observed by splenocytes from Ron
TBM compared with that of splenocytes from control animals (Fig. 8B) . Ag-specific rechallenge with gamma-irradiated tumor cells elicited a trend toward increased production of IFN-g and decreased production of IL-10 ( 
Discussion
Recent studies using Arg1-deficient bone marrow or macrophagespecific Arg1 knockouts have found that immune cell/macrophagederived Arg1 is critical for suppressing inflammation and fibrosis during infection with Th2-inducing pathogens (5). However, Arg1 expression is also upregulated in the absence of Th2-mediated inflammation (37) , suggesting that IL-4/IL-13-independent mechanisms governing Arg1 expression exist in vivo. Previously, we demonstrated that MSP, the ligand for the Ron receptor tyrosine kinase, induces Arg1 expression in resident peritoneal macrophages in the absence of Th2 cytokines (29) . In this study, we show that this induction is mediated by an AP-1 site in the Arg1 promoter. Furthermore, we demonstrate that Ron promotes Arg1 expression in TAMs, associated with increased tumor growth and decreased T cell-mediated immunity in the presence of Ron. These findings highlight the importance of Ron in the induction of Arg1 expression in vivo. The lower expression levels of Ron in TEMs compared with peritoneal macrophages raises the possibility that the ability of Ron to promote Arg1 expression in vivo could be due to both cell autonomous and non-autonomous regulation.
The AP-1 site identified in this study is not the only functional AP-1 site in the murine Arg1 promoter. An AP-1 site located 3157 were isolated by FACS from MMTV-PyMT spontaneous mammary tumors. Expression of Ron and Arg1 in these macrophage subsets was assessed by qPCR and is expressed as relative to expression in inflammatory TAMs. To calculate differences in mRNA levels, b2m and Gapdh were used as reference genes for Ron and Arg1, respectively. Statistical analysis of the data was performed on actual DC t values by Student t test on two biological replicates. E and F, Expression of Ron and Arg1 in TEMs, inflammatory TAMs, and unstimulated peritoneal macrophages or macrophages stimulated with IFN-g and LPS or IL-4 was assessed by qPCR and normalized to b2m. To compare mRNA levels, Ron and Arg1 mRNA copies are expressed as relative to b2m mRNA copies. Statistical analysis of the data was performed on actual DC t values by Student t test on three (TEMs and inflammatory TAMs) or two (resident peritoneal macrophages) biological replicates. iTAMs, inflammatory TAMs; WT, wild type. bp upstream of the TSS was recently shown to be required for induction of Arg1 in endothelial cells by thrombin (38) . Promoter fragments containing the AP-1 site at 2433 were not inducible by thrombin. In contrast to MSP induction of Fos binding to the 2433 AP-1 site, thrombin activation of the Arg1 promoter involved binding of c-Jun and activating transcription factor-2 to the 23157 AP-1 site (38) . AP-1 is composed of homodimers and heterodimers of various Jun, Fos, and activating transcription factor family members. Thus, activation of different AP-1 elements within the Arg1 promoter may reflect tissue-specific differences in expression of various AP-1 family members and/or specific sequence contexts in which the AP-1 sites reside.
Although MSP induces robust phosphorylation of Stat6 in primary macrophages (data not shown), we observed little or no binding of Stat6 to the Arg1 promoter after MSP stimulation, and mutation or deletion of the Stat6 binding site in the Arg1 promoter did not affect induction of the promoter by MSP. This is consistent with the observation that MSP does not induce expression of the Stat6-dependent genes Chi3l3 (Ym1) and Retnla (Fizz1). Moreover, MSP inhibits the expression of Chi3l3 and Retnla in response to IL-4, suggesting that MSP likely inhibits Stat6 transcriptional activity. However, induction of Arg1 by IL-4 is maintained in the presence of MSP, highlighting the differential regulation of Arg1 and other M2 markers. These results are consistent with the observation that Ron wild-type and Ron 2/2 TBM were euthanized on days 7, 11, and 15, and serum was collected by cardiac puncture. Serum was analyzed using a lincoplex assay for (A) MCP-1, (B) G-CSF, (C) IL-6, and (D) IL-1a. Day 7: wild type (n = 7), Ron Cx 3 CR1, and CD43 (39, 40) . The so-called "resident" population of circulating monocytes may provide a source of tissueinfiltrating macrophages, which tend to be more M2-polarized than inflammatory macrophages and play an important trophic role by promoting tissue healing after inflammatory damage (41) . Our observation that Ron is expressed predominantly by the MRC1 + subpopulation of TAMs, which are hypothesized to derive from circulating "resident" monocytes and promote tumor growth (15) , is consistent with the restricted expression of Ron on resident macrophages and its role in protecting tissues from inflammatory damage (24) .
Regulating the balance of M1 versus M2 activation of TAMs has a major impact on tumor growth, and expression of Arg1 by TAMs plays a key role in this regulation. mediated immunity (10) . Thus, while the enhanced T cell activity in the spleens of Ron 2/2 TBM correlates with a decrease in splenic MDSCs, the induction of Arg1 by Ron in TAMs could also contribute to the inhibition of T cell-mediated immunity within the tumor microenvironment, which would cooperate with the proangiogenic and tissue-remodeling programs of TAMs to favor tumor growth. Recent studies demonstrate that the multitarget RTK inhibitor, sunitinib malate, inhibits tumor cell growth and also promotes tumor immunity in both a mouse model and human clinical trials (44, 45) . Although the effect of sunitinib on TAM activity is currently unknown, these studies provide proof of principle that targeting RTK activity in the tumor microenvironment could be therapeutically beneficial. Our studies indicate that the absence of Ron in the tumor microenvironment results in reduced Arg1 expression by TAMs, potentially contributing to the decreased tumor growth observed in Ron 2/2 mice. Thus, understanding the molecular mechanism by which Ron promotes Arg1 expression is an important step in the development of therapies aimed at targeting macrophage regulation of tumor growth. The widespread overexpression of Ron in epithelial carcinomas, as well as its ability to induce tumor-promoting activities in infiltrating TAMs, renders Ron a promising therapeutic target for a wide range of malignancies.
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